Background: Traditional approaches to pharmacovigilance center on the signal detection from spontaneous reports, e.g., the U.S. Food and Drug Administration (FDA) adverse event reporting system (FAERS). In order to enrich the scientific evidence and enhance the detection of emerging adverse drug events that can lead to unintended harmful outcomes, pharmacovigilance activities need to evolve to encompass novel complementary data streams, for example the biomedical literature available through MEDLINE.
Introduction
The timely identification of adverse drug events (ADEs) during the post-approval phase is an important goal of the public health system. Undetected ADEs result in potentially preventable harm to a substantial number of patients and impose a significant burden on the healthcare system [1] [2] [3] [4] .
While the U.S. Food and Drug Administration (FDA) collects and analyzes drug safety reports through the FDA Adverse Event Reporting System (FAERS) 5 , the systematic inventory and collection of ADEs in structured form remains a challenge. Moreover, given well-recognized limitations with such systems 6 , pharmacovigilance activities must evolve to encompass novel complementary data streams, in order to enrich the scientific evidence and enhance the detection of emerging adverse drug events that can lead to unintended harmful outcomes.
Text mining techniques have been used to extract ADEs from various sources 7 . Several recent and ongoing projects have attempted to extract ADEs from the DailyMed structured product labels (e.g., 8 ), clinical narratives (e.g., [9] [10] [11] [12] ), electronic health records (e.g., [13] [14] [15] [16] ), the social media (e.g., 17 ), and from the biomedical literature, especially MEDLINE ® (e.g., 9, 18, 19 ).
The biomedical literature contains valuable information about ADEs in the form of case reports, clinical studies, and observational studies. This information enables drug safety evaluators to assess potentially new ADEs, such as those identified through FAERS. In addition, the biomedical literature may contain ADEs that are not detectable through systems such as FAERS, because healthcare practitioners or researchers are more enthusiastic about publishing their ADE-related findings in scientific journals than reporting them to systems such as FAERS.
Moreover, MEDLINE is one of the largest and most comprehensive biomedical literature databases with a broad diversity of human, animal, and in vitro data presented in a variety of publication types. In contrast to FAERS, MEDLINE also offers the advantage of providing scientific information that spans the entire life cycle of a drug from early pre-market drug development through useful market life. This makes the biomedical literature a very important source of information about ADEs.
d r a f t
Unlike systems such as FAERS, the new data sources that are now being considered for ADE detection, such as the biomedical literature, were not created specifically for ADE-related applications, and therefore necessitate different approaches to uncover ADEs.
In the MEDLINE database, ADEs are not only expressed in natural language form in the title and abstract, but also in structured form through MeSH indexing. In MEDLINE, citations are indexed with Medical Subject Headings (MeSH ® ) descriptors (or "main headings"), e.g., for diseases or drugs, that are often enriched with qualifiers (or "subheadings") that express the specific context in which a topic (e.g., the drug Levofloxacin) is discussed in a given citation However, there are complexities and limitations to extracting ADEs from MEDLINE indexing.
For example, while most ADEs are indexed through the combination of a disease descriptor and the chemically induced qualifier (e.g., Tendinopathy/chemically induced), others, because they are more frequent or important, are completely reflected by a descriptor alone (e.g., DrugInduced Liver Injury) and would not be found by searching the corresponding combination (Liver Diseases/chemically induced). In practice, detailed knowledge about the characteristics of MEDLINE indexing is essential to complete and accurate retrieval of ADEs.
Although our approach to extracting ADEs from MEDLINE indexing is generally similar to Avillach's, the goals of the two projects are different. Avillach et al. are primarily interested in detecting known ADEs in MEDLINE, while our goal is to systematically harvest all ADEs from MEDLINE, already known or not, in order to support signal detection in pharmacovigilance.
Therefore, our strategy for identifying ADEs tends to be more aggressive and goes beyond the simple co-occurrence of descriptor-qualifier pairs pioneered by Avillach. In a pilot study designed to expand the scope of resources beyond FAERS, we assessed the feasibility of detecting drug-adverse event safety signals for fluoroquinolones through quantitative data mining of MEDLINE indexing terms 21 .
The objectives of this work are 1) to review how the characteristics of MEDLINE indexing influence the identification of ADEs; 2) to leverage this knowledge to inform the design of a system for extracting ADEs from MEDLINE indexing; and 3) to assess the specific contribution of some characteristics of MEDLINE indexing to the performance of this system.
Background
In this section, we review some of the characteristics of MEDLINE indexing and analyze their influence on the identification of ADEs from MEDLINE indexing. In the course of our research,
we have identified nine of these characteristics as potential issues, and have discussed them with MEDLINE indexing specialists at the National Library of Medicine (NLM). The list of these issues is provided in Table 1 . Each issue is presented in detail later in this section. We have developed mitigation strategies for three of these issues (1-3), which we have integrated in the design of our system for identifying ADEs from MEDLINE indexing. For the other issues, we provide some recommendations in the discussion section. d r a f t clinical trials (usually not large enough to detect rare events, since the study populations are usually sized towards efficacy). Conversely, it is unlikely that an overall safety profile for a drug can be derived from case reports alone.
MEDLINE does not record a relation between a drug and the manifestation of an adverse event
MeSH index terms for a given citation are provided as a flat list and are generally independent of one another. In fact, in the context of adverse events, it should be noted that the MEDLINE indexers have no way to annotate an ADE pair directly, i.e., to link a drug and a disease for this ADE. Instead, the index will contain a drug qualified by adverse effects and a disease term qualified by the chemically induced. Co-occurrence of the two index terms in a citation is no guarantee for the existence of a direct link between them.
The implicit nature of these co-occurrence relationships is especially problematic when ADE articles are indexed with more than one drug or more than one disease term. For example, a recent study on the prevention and management of major side effects of breast cancer drugs is indexed with the adverse events cardiovascular, gastrointestinal, and skin diseases, as well as the antineoplastic agents lapatinib, bevacizumab, and trastuzumab 22 . Without further information, the simplest assumption is that each of the drugs is possibly responsible for each of the ADEs mentioned (cross-product).
MeSH descriptors sometimes conflate several drugs
MeSH descriptors, which are used for indexing documents in MEDLINE, are in fact small aggregates of concepts, grouped together as needed to support indexing and retrieval 23 . For example, the MeSH descriptor Citalopram (D015283) is used for indexing not only the drug citalopram (as expected), but also its stereoisomer, the drug Escitalopram. Although
Escitalopram is arguably a separate drug (with specific brand names), it does not exist in MeSH outside the descriptor Citalopram, making it impossible to distinguish between the two drugs on the basis of the index alone.
Nowadays MeSH tends to create distinct descriptors for most major drugs. For example, a descriptor was recently developed for Levofloxacin, distinct from the descriptor Ofloxacin under which it was grouped prior to 2014. However, granularity issues still exist for some drugs, such
as Abatacept / Belatacept, Dropropizine / Levodropropizine, and Sultopride / Amisulpride.
MEDLINE indexing rules sometimes aggregate multiple drugs under a broader MeSH descriptor
Although MEDLINE indexers usually select the most specific descriptors for the topics discussed in an article, according to the indexing rule "Rule of Three", a group of three or more specific descriptors must be replaced by one more general descriptor, if these specific terms are treed under the more general one. For example, although an article about fluoroquinoloneassociated myasthenia gravis exacerbation 24 mentions several individual fluoroquinolones in its abstract (levofloxacin, moxifloxacin, ciprofloxacin, ofloxacin, gatifloxacin, norfloxacin, and trovafloxacin), the article is not indexed with any of these drug terms but with the more general descriptor Fluoroquinolones instead.
d r a f t
One consequence of the Rule of Three is that some adverse events are captured at the class level rather than at the level of individual drugs. This problem might be less prominent in case reports, which focus often on fewer individual drugs than, for instance, research and review articles.
Changes to MeSH have consequences on the retrieval of ADEs
The MeSH terminology is not static but evolves over time to reflect changes in biomedical knowledge, as well as terminology editorial policies. As mentioned before, MeSH descriptors sometimes group several related concepts. These groupings change over time as part of the evolution of MeSH. with the descriptor Ofloxacin (see Figure 2 ). In the case of Levofloxacin, the new descriptor was actually added retrospectively to citations previously indexed with Ofloxacin, if the string
"levofloxacin" appears in the title or abstract. In many other cases, however, the indexing of older citations is not modified to reflect descriptors recently added to MeSH.
While the retrospective addition of more specific index terms is generally beneficial to retrieval, it also creates some issues. The first issue is ambiguity. In practice, in articles such as this review article from 2009 reporting on seizures associated with Levofloxacin 25 , it is not possible to distinguish from the indexing between citations about levofloxacin originally indexed with
Ofloxacin, and to which Levofloxacin was later added, and citations natively indexed with both
Ofloxacin and Levofloxacin. Moreover, a second issue arises from the fact that the qualifiers originally attached to the broader descriptor Ofloxacin were not transferred to the more specific descriptor Levofloxacin when it was retrospectively assigned to the citation. As a consequence, in order to identify ADEs from the indexing, the adverse effect qualifier attached to the broader 
Medical Subject Headings (MeSH)
The 
RxNorm
RxNorm is a standardized nomenclature for medications produced and maintained by the U.S. 
Methods and Results
In this section, we present the system we have created for extracting ADEs from MEDLINE indexing. In addition to extracting basic co-occurrences between a drug entity, qualified by the adverse effects qualifier, and a disease descriptor, qualified by chemically induced, we introduce
two types of refinement leveraging the characteristics of MEDLINE indexing discussed in the Background section. The first refinement consists of the addition of descriptors, which, in the absence of a chemically induced qualifier, already denote adverse events. We also make sure we capture all drug entities bearing the ADE context (i.e., qualified not only by adverse effects, but also by the qualifiers it subsumes, namely poisoning or toxicity, as well as contraindications). In the second major refinement, we consider indirect links between drug entities and broader drug descriptors bearing the ADE context, attempting to "transfer" the denotation of ADEs to finegrained drug entities. These two refinements are not modular additions to the system, but rather integral to it. However, we keep provenance information about each ADE we extract, making it possible to analyze the specific contribution of each part of the system. After the system design, we present an evaluation, both quantitative and qualitative, of the specific contribution of the two refinements made to the baseline system.
System design
Our approach to extracting ADEs from MEDLINE indexing can be summarized as follows.
First, we run a query against the MEDLINE database to retrieve all articles that are relevant in d r a f t 14 the context of adverse drug events. In each article, we identify among the MeSH indexing terms those that represent the drugs and diseases involved in an ADE. Finally, we extract the drugmanifestation pairs, along with provenance and metadata information (e.g., publication type).
Step 1: Identifying MEDLINE citations corresponding to ADEs
We designed a broad query to be run against the MEDLINE database capturing all citations with at least one drug in the context of adverse effects (drug facet) and one chemically induced manifestation (manifestation facet). The query is shown in Figure 3 . 
Step 2: Identifying index terms for drugs and manifestations involved in ADEs
In this second step, we identify index terms for drugs and manifestations involved in ADEs among the MEDLINE citations retrieved at Step 1.
Drugs
For a given citation, we consider as drug candidates all indexed descriptors that are located in the
Chemicals and Drugs tree in MeSH as well as all supplementary concept records, if any, that are connected to any of these descriptors through Heading Mapped to or pharmacological action
relationships. We leverage information from the MeSH terminology to reconstruct all hierarchical relationships between all drug candidates for a given citation, see Figure 4 . We use the hierarchical information to report only on terms with highest specificity, i.e., the leaf nodes in the reconstructed tree, whereby information from qualifiers, i.e., the active role in adverse effects, poisoning, toxicology, or contraindications, can be passed on from higher level terms to their children. For example, if a citation contains the SCR mivacurium, the structural descriptor d r a f t
Isoquinolines, and the pharmacological action descriptor Neuromuscular Nondepolarizing
Agents, with relations as depicted in Figure 1 , we identify only the SCR as the ADE drug.
Furthermore, this SCR "inherits" the adverse effects (AE) qualifier from the descriptor and the PA, respectively, and will be considered as an involved drug in this citation. Conversely, if a specific drug does not bear the ADE context (directly or indirectly), it is recorded as a concomitant drug.
Figure 4: Relations between MESH terms representing drugs or drug classes in MEDLINE indexing

AE manifestations
For a given citation, we consider as manifestations of an adverse event all descriptors from the citation's index that are further qualified by the qualifier chemically induced, as well as any of the 19 pre-coordinated descriptors from Table 2 .
Step 3: Extracting ADE pairs and metadata
In the third component of our system, we extract the ADE pairs based on the entities identified in
Step 2, filter them for clinical relevance, and enrich the ADE pairs with metadata information.
ADE pairs
As mentioned before, ADE pairs are not explicitly given as part of the MEDLINE indexing.
Instead, we reconstruct the pairs based on the drugs and event manifestations individually identified in Step 2. We derive the ADE pairs for a given citation by applying the Cartesian product between all specific drugs and all AE manifestations. The role of a given drug in an d r a f t ADE pair is then classified as either involved or concomitant, based on the presence or absence of the appropriate qualifiers for this drug. 
Metadata
Besides drugs and adverse events, we extract additional information that could be relevant in the context of signal detection for pharmacovigilance. In addition to identifying drugs as involved or concomitant, we systematically collect MeSH terms providing information about species (B01 subtree), gender ("male" or "female"), age groups (M01.060 subtree), publication types (V tree), epidemiologic methods (E05.318 subtree), and the indication of a drug (any descriptor with the qualifier drug therapy), whenever available. Additionally, we extract publication dates from various data elements in the XML file of each citation. Based on these data, we can later easily refine the analysis of our data (e.g., restricted to ADEs found in case reports), compare different cohorts within one set (male vs. female, studies in animals vs. humans), or determine when information about a specific ADE was published for the first time.
d r a f t
Experiments
Two levels of refinement over the baseline
As mentioned earlier, our approach to extracting ADEs from MEDLINE indexing integrates two levels of refinement over the baseline, namely an extension of the scope of descriptors and qualifiers for ADEs, and the possibility for a drug descriptor to "inherit" the ADE context (qualifier) placed on a broader drug descriptor. The list of features corresponding to each level of refinement is summarized in Table 3 . While these refinements are already built into our system, we measure the specific contribution of each level by tracking at which level (Baseline, Extension, Inheritance) a given ADE is extracted.
Baseline
This is the most restrictive of the three levels and corresponds to a naïve approach to extracting
ADEs from MEDLINE indexing (basic co-occurrence of descriptor-qualifier pairs for drugs and manifestations in the context of ADEs).
• The only qualifier we consider for drugs is adverse effects [Feature 1 in Table 3 ]. The qualifier contraindications, as well as the two qualifiers grouped under adverse effects, namely poisoning and toxicity, are not considered.
• Manifestations of adverse events are only identified by descriptors qualified by the chemically induced qualifier [Feature 14 in Table 3 ]. The 19 pre-coordinated manifestation descriptors are not considered.
• No indirect inheritance of the ADE context is allowed. In practice, drug descriptors are considered only if they are directly qualified by adverse effects [Feature 9 in Table 3 ];
SCRs inherit the adverse effects qualifier only from the descriptors to which they have direct Heading Mapped to or Pharmacologic Action relations [Features 5-6 in Table 3 ].
Extension of the scope of descriptors and qualifiers for ADEs
In addition to all the features of the baseline, we extend the scope of descriptors and qualifiers for ADEs, by allowing additional (unqualified) descriptors and additional qualifiers.
• In addition to the qualifier adverse effects, we consider the qualifier contraindications, as well as the two qualifiers grouped under adverse effects, namely poisoning and toxicity [Features 2-4 in Table 3 ].
• In addition to the descriptors qualified by the chemically induced qualifier, we consider the 19 pre-coordinated manifestation descriptors [Feature 15 in Table 3 ].
• As for the baseline, no indirect inheritance of the ADE context is allowed.
Inheritance of the ADE context
At this level, we apply all the strategies from the Baseline and Extension levels. 
Specific contribution of each level
In the following we provide a quantitative evaluation of the results of our system, in terms of extracted drugs, manifestations, and ADE pairs, focusing on the specific contribution of each level. Table 4 shows the cumulative results and the relative gain for the three levels. 
Inheritance
The overall contribution of this level is marginal in comparison to the first two levels. We only retrieve 15 additional drugs and 10 additional manifestations, nonetheless yielding 5,267 additional unique ADEs and 22,889 additional ADE instances. Again, 6,262 of these ADE instances refer to drug-manifestation pairs that could not be captured at the Baseline or Extension levels. We harvest information from 205,597 of the 360k citations retrieved by our broad MEDLINE query. (The remaining 160k MEDLINE citations may contain ADE pairs for drugs that are not clinically relevant, chemicals, drug combinations, or drug classes, all of which are ignored on purpose by our RxNorm filter).
Evaluation
By measuring the specific contribution of each level, we were able to demonstrate that the two levels of refinement over the baseline yielded significant numbers of additional ADEs, including novel ADEs that could not be captured at previous levels. While these additional levels are obviously productive, we need to evaluate if the additional ADEs obtained are valid. We do not evaluate the quality of the ADEs at the Baseline level, because ADEs extracted by similar approaches have already been evaluated by others (e.g., Avillach et al 20 ) .
In order to evaluate the quality of the ADEs extracted at the Extension and Inheritance levels, we focus on the novel ADEs extracted at these levels, i.e., unique ADEs that could not be extracted at previous levels. (That is, we do not review additional instances for ADEs already extracted at previous levels). One of the authors (AS), a physician, manually compared a subset of ADE pairs extracted at each level against the information available in the titles and abstracts of the corresponding articles in MEDLINE. We excluded ADEs from articles without abstracts from this evaluation. We randomly sampled 90 of the 45,978 novel ADE instances in the Extension set and 34 of the 6,262 novel ADE instances in the Inheritance set. For each ADE instance, we evaluated if the information in the title or abstract provided evidence for ("positive"), evidence against ("negative"), or no evidence for ("neutral") the ADE instance. Because articles are indexed based on the full article, absence of evidence for an ADE in the title or abstract does actually not mean that evidence would not be found in the full text. For this reason, we provide two flavors of the evaluation: one best case scenario, in which the "neutral" and "positive" cases are considered together, and one worst case scenario, in which the "neutral" and "negative" cases d r a f t 22 are considered together. Table 5 shows the detailed results of our evaluation. Considering the worst and best case scenarios, the ADE pairs extracted in the Extension level are between 71 and 96% correct, whereas the ADE pairs extracted in the Inheritance level are between 26 and 74% correct. ADEs would be missed if it were not for the Inheritance level. We manually reviewed the quality of ADE pairs for these specific drugs and found that they are between 44 and 88% correct, which is an improvement over the 26 and 74% for random drugs (Table 5 ). Our recommendation is therefore to apply the Extension level not to all drugs, but only to those MeSH descriptors that have undergone recent changes and for which the ADE context may be borne by another descriptor as a result of these changes. 
Discussion
We outline the significance of our findings, present lessons learned and recommendations, contrast text mining with data mining for ADE extraction, and discuss some limitations and future work.
Significance
In this work we investigated the properties and limitations of MEDLINE indexing for use in pharmacovigilance. We identified nine MEDLINE indexing properties that affect the manner in which ADEs can be identified and extracted. Based on these findings we proposed a comprehensive approach for the extraction of ADEs from MEDLINE indexing.
Our evaluation reinforces the notion presented in earlier studies that the use of MEDLINE indexing is a viable approach for extracting valuable safety information from the biomedical literature. In addition, we demonstrate that our approach provides an improvement over existing For a small number of drugs, ADEs can be captured only by considering indirect links between a specific drug and the broader descriptor bearing the ADE context. While this phenomenon is only marginally important overall, this is very important for specific drugs (e.g., levofloxacin).
However, it should not be applied across the board, as its performance is generally limited.
From studying the characteristics of MEDLINE indexing
ADEs indexed with MeSH are skewed towards case reports
ADEs extracted from MEDLINE are not sufficient for signal detection for pharmacovigilance, as most of the ADEs indexed come from case reports, in which the ADEs reported are not representative of all ADEs. Therefore, the integration of multiple sources of information beyond the biomedical literature is likely to be critical in order to obtain comprehensive drug safety information. MEDLINE indexing should be considered as one source of ADE information, along with spontaneous reporting (FAERS), observational data (from electronic health records), etc.
MEDLINE does not record a relation between a drug and the manifestation of an adverse event
The overall quality (i.e., signal-to-noise ratio) of the data originating from peer-reviewed and manually indexed articles should be generally higher than, for instance, the quality of the raw data submitted to the FDA Adverse Event Reporting System (FAERS), where consumers might d r a f t 26 report entire medication lists alongside the list of symptoms they experienced. Overall, despite potential false positives, the ADEs extracted from MEDLINE indexing are expected to be more targeted than those from spontaneous reporting systems.
MeSH descriptors sometimes conflate several drugs
Although we showed this was a problem for some drugs (e.g., levofloxacin), the impact of this characteristic of MeSH indexing is limited overall. Moreover, over the past years, MeSH has created distinct descriptors for most major drugs. However, the evolution of the MeSH vocabulary for drugs that were once conflated into one descriptor should be taken into account for the analysis of specific drugs.
MEDLINE indexing rules sometimes aggregate multiple drugs under a broader
MeSH descriptor
This issue is an indexing issue, independent from the organization of the MeSH vocabulary itself. Although we have not specifically measured its impact, we suspect it is limited overall.
Moreover, this rule applies not to specific drugs, but to all MeSH descriptors. Therefore, it
should not have introduced any bias towards specific ADEs.
Changes to MeSH have consequences on the retrieval of ADEs
This issue is a consequence of the evolution of the MeSH vocabulary, especially when drugs that were conflated under the same descriptor become distinct descriptors. As mentioned earlier, while important for specific drugs, the impact of this issue is marginal overall.
MEDLINE indexing is not always immediately available at publication time
As a consequence, ADEs extracted from MEDLINE indexing cannot be expected to be immediately available at publication time. This lag time must be taken into account when extracting ADEs (or other information) from MEDLINE indexing.
Text mining vs. data mining for ADE extraction
It is worth noting the parallel efforts for extracting ADEs from the biomedical literature, which apply natural language processing (NLP) techniques to article titles and abstracts 9, 18, 19 . Given 
Analysis of the signal generated
It was beyond the scope of this investigation to determine which statistical techniques would be best for analyzing the signal generated from MEDLINE indexing. Similarly, we chose to follow a search and extraction strategy that retrieves a broad set of ADEs for a diverse set of chemicals and drugs from various types of publications and studies. While Avillach filtered out some publication types as non-contributory 20 , and Gurulingappa only considered case-reports 19 , we chose to be inclusive of all publication types and to capture provenance information, rather than making an a priori selection. This strategy provides greater flexibility and supports refinements of the statistical analysis as needed.
Conclusions
To enhance the detection of emerging adverse drug events that can lead to unintended harmful outcomes, pharmacovigilance activities needs to evolve to encompass novel complementary data streams, for example the biomedical literature available through MEDLINE.
In this investigation, we focused on the extraction of ADEs from MEDLINE indexing. We confirmed that the analysis of co-occurrence of descriptor-qualifier pairs remains a valid strategy. We proposed significant improvements over a baseline approach, in order to mitigate some of the inherent limitations of MEDLINE indexing for pharmacovigilance. The system we created successfully extracted 405,300 ADE instances from 205,597 MEDINE citations vs.
297,093 ADE instances from 198,676 citations for the baseline system. We verified that the majority of these additional ADE instances are correct.
ADEs extracted from MEDLINE indexing for pharmacovigilance purposes are complementary to, not a replacement for, other sources. ADEs could not be reliably extracted from MEDLINE indexing if MEDLINE did not provide fine-grained indexing, not only at the level of individual drugs and manifestations, but also reflecting the specific ADE context for these index terms.
